在帕博利珠单抗治疗转移性黑色素瘤期间发生的皮肤CD56 T细胞淋巴瘤。 - Suppr

Suppr

超能文献

Cutaneous CD56 T-cell lymphoma developing during pembrolizumab treatment for metastatic melanoma.

作者信息

Zheng Yixuan James, Lee Albert, Pincus Laura, Ho Wilson, Vujic Marin, Ortiz-Urda Susana

机构信息

University of California, San Francisco Mt. Zion Cancer Research Center, San Francisco, California.

University of California, San Francisco Medical Center, San Francisco, California.

出版信息

JAAD Case Rep. 2018 Jun 6;4(6):540-542. doi: 10.1016/j.jdcr.2018.01.016. eCollection 2018 Jul.

DOI:10.1016/j.jdcr.2018.01.016

PMID:29892669

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5991899/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc1d/5991899/6d2a640d9dda/gr1.jpg

相似文献

Cutaneous CD56 T-cell lymphoma developing during pembrolizumab treatment for metastatic melanoma.在帕博利珠单抗治疗转移性黑色素瘤期间发生的皮肤CD56 T细胞淋巴瘤。

JAAD Case Rep. 2018 Jun 6;4(6):540-542. doi: 10.1016/j.jdcr.2018.01.016. eCollection 2018 Jul.

Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma.抗程序性死亡1抗体联合抗细胞毒性T淋巴细胞相关蛋白4疗法在转移性黑色素瘤患者中应用的皮肤不良事件

Melanoma Res. 2019 Apr;29(2):172-177. doi: 10.1097/CMR.0000000000000518.

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.程序性细胞死亡蛋白1或联合程序性死亡蛋白1/细胞毒性T淋巴细胞相关抗原4抑制治疗转移性葡萄膜黑色素瘤的预后因素及结局

Eur J Cancer. 2017 Sep;82:56-65. doi: 10.1016/j.ejca.2017.05.038. Epub 2017 Jun 22.

Pembrolizumab.帕博利珠单抗。

J Immunother Cancer. 2015 Aug 18;3:36. doi: 10.1186/s40425-015-0078-9. eCollection 2015.

Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers.肿瘤患者接受非黑色素瘤转移性癌症免疫治疗后出现白癜风样脱色。

Clin Exp Dermatol. 2019 Aug;44(6):643-646. doi: 10.1111/ced.13867. Epub 2019 Jan 7.

Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.抗程序性细胞死亡（PD）-1 治疗转移性黑色素瘤患者的皮肤不良事件（AE）：单机构队列。

J Am Acad Dermatol. 2016 Mar;74(3):455-61.e1. doi: 10.1016/j.jaad.2015.10.029. Epub 2016 Jan 12.

Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.抗程序性死亡-1药物治疗后不良事件的管理

Oncologist. 2016 Oct;21(10):1230-1240. doi: 10.1634/theoncologist.2016-0055. Epub 2016 Jul 8.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.

[Understanding current therapies in metastatic melanoma].[了解转移性黑色素瘤的当前治疗方法]

Rev Med Chil. 2016 Nov;144(11):1448-1458. doi: 10.4067/S0034-98872016001100011.

Cutaneous adverse effects of the immune checkpoint inhibitors.免疫检查点抑制剂的皮肤不良反应。

Curr Probl Cancer. 2017 Mar-Apr;41(2):125-128. doi: 10.1016/j.currproblcancer.2016.12.001. Epub 2016 Dec 14.

引用本文的文献

Late-Onset Angioimmunoblastic T-cell Lymphoma During Nivolumab Treatment for Melanoma.黑色素瘤患者接受纳武单抗治疗期间发生的迟发性血管免疫母细胞性T细胞淋巴瘤

Cureus. 2025 Jul 30;17(7):e89042. doi: 10.7759/cureus.89042. eCollection 2025 Jul.

Drug- and Vaccine-Induced Cutaneous T-Cell Lymphoma: A Systematic Review of the Literature.药物和疫苗诱导的皮肤T细胞淋巴瘤：文献系统评价

J Skin Cancer. 2025 Feb 27;2025:3103865. doi: 10.1155/jskc/3103865. eCollection 2025.

Abrupt progression from patch- to tumor-stage mycosis fungoides following pembrolizumab treatment.帕博利珠单抗治疗后蕈样肉芽肿从斑块期迅速进展至肿瘤期。

JAAD Case Rep. 2024 May 6;49:129-131. doi: 10.1016/j.jdcr.2024.03.028. eCollection 2024 Jul.

Sézary syndrome associated vitiligo-like leukoderma in type V skin: Report of a case and review of the literature.V型皮肤中与蕈样肉芽肿相关的白癜风样白斑：一例报告及文献复习

JAAD Case Rep. 2024 Apr 15;48:103-107. doi: 10.1016/j.jdcr.2024.04.009. eCollection 2024 Jun.

Cutaneous T cell lymphoma.皮肤 T 细胞淋巴瘤。

Nat Rev Dis Primers. 2021 Aug 26;7(1):61. doi: 10.1038/s41572-021-00296-9.

CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.长期纳武利尤单抗治疗晚期肺腺癌后患者出现 CD8 阳性外周 T 细胞淋巴瘤：一例报告。

Thorac Cancer. 2021 Jun;12(11):1765-1769. doi: 10.1111/1759-7714.13966. Epub 2021 May 3.

Updating targets for natural killer/T-cell lymphoma immunotherapy.更新自然杀伤/T 细胞淋巴瘤免疫治疗的目标。

Cancer Biol Med. 2021 Feb 15;18(1):52-62. doi: 10.20892/j.issn.2095-3941.2020.0400.

Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.免疫检查点抑制剂在非霍奇金淋巴瘤中的当前临床应用和未来展望。

J Immunol Res. 2020 Oct 29;2020:9350272. doi: 10.1155/2020/9350272. eCollection 2020.

Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.纳武利尤单抗治疗同时患有黑色素瘤和蕈样真菌病的患者：T 淋巴瘤细胞减少和免疫增强。

Front Immunol. 2020 Sep 25;11:579894. doi: 10.3389/fimmu.2020.579894. eCollection 2020.

Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation.阻断蕈样肉芽肿综合征中程序性细胞死亡蛋白1（PD-1）可降低非肿瘤性T淋巴细胞的Th2表型，但可能增强肿瘤增殖。

Oncoimmunology. 2020 Mar 18;9(1):1738797. doi: 10.1080/2162402X.2020.1738797. eCollection 2020.

本文引用的文献

Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy.帕博利珠单抗治疗继发的抗接触蛋白相关蛋白样2抗体自身免疫性边缘叶脑炎

J Neuroimmunol. 2017 Apr 15;305:16-18. doi: 10.1016/j.jneuroim.2016.12.016. Epub 2017 Jan 18.

PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.帕博利珠单抗的 PD1 阻断在 l-天冬酰胺酶治疗失败的复发或难治性 NK/T 细胞淋巴瘤中具有高度疗效。

Blood. 2017 Apr 27;129(17):2437-2442. doi: 10.1182/blood-2016-12-756841. Epub 2017 Feb 10.

Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease: A Report of 2 Patient Cases.帕博利珠单抗治疗引发既往自身免疫性疾病恶化：2例患者报告

J Investig Med High Impact Case Rep. 2016 Oct 25;4(4):2324709616674316. doi: 10.1177/2324709616674316. eCollection 2016 Oct-Dec.

Pembrolizumab-associated sarcoidosis.帕博利珠单抗相关的结节病。

JAAD Case Rep. 2016 Jul 27;2(4):290-3. doi: 10.1016/j.jdcr.2016.06.004. eCollection 2016 Jul.

BMC Med. 2015 Sep 4;13:211. doi: 10.1186/s12916-015-0455-8.

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.帕博利珠单抗的皮肤不良事件及其与疾病进展的关联。

JAMA Dermatol. 2015 Nov;151(11):1206-1212. doi: 10.1001/jamadermatol.2015.1916.

Highlights in pathogenesis of vitiligo.白癜风发病机制要点。

World J Clin Cases. 2015 Mar 16;3(3):221-30. doi: 10.12998/wjcc.v3.i3.221.

At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.在实验台上：CTLA-4 和 PD-1 阻断作为癌症免疫疗法的临床前原理。

J Leukoc Biol. 2013 Jul;94(1):25-39. doi: 10.1189/jlb.1212621. Epub 2013 Apr 26.

PD-1 signaling in primary T cells.初始T细胞中的PD-1信号传导。

Immunol Rev. 2009 May;229(1):114-25. doi: 10.1111/j.1600-065X.2009.00767.x.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验